Drug Type AAV based gene therapy |
Synonyms Anti-CD19/CD22 chimeric antigen receptor T cell therapy - Avalon GloboCare |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors), Immunologic cytotoxicity + [1] |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | CN | 23 Jun 2019 | |
Non-Hodgkin Lymphoma | Preclinical | US | - | |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Preclinical | US | - | |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Preclinical | US | - |